Strand Life Sciences bioinformatics company and a subsidiary of Reliance Industries Limited have introduced CancerSpot, a revolutionary blood-based test for the early detection of multiple cancers. Employing state-of-the-art methylation profiling technology, CancerSpot identifies DNA methylation signatures of tumor DNA from a simple blood sample, offering a proactive and accessible approach to cancer screening.
CancerSpot’s proprietary genome sequencing and analysis process, developed using robust data from Indian cohorts, ensures applicability across global ethnicities. This innovation provides a groundbreaking alternative for routine cancer screening, empowering individuals with the opportunity to detect cancer at its earliest stages.
Emphasising the test’s potential impact, Isha Ambani Piramal, Member of the Board, Reliance Industries, said, "Cancer is becoming a major cause of morbidity and mortality in India, imposing financial, social, and psychological burdens on patients and families. Strand’s novel cancer early detection test is a testament to Reliance’s commitment to delivering transformative healthcare solutions. This aligns with our ‘WE CARE’ philosophy, translating into impactful initiatives like the Genomics Diagnostics & Research Centre.”
New Genomics Diagnostics & Research Centre
The launch coincided with the inauguration of Strand’s new Genomics Diagnostics & Research Centre in Bengaluru. This state-of-the-art, 33,000-square-foot facility features advanced sequencing technologies and a collaborative environment for bioinformatics experts, molecular biologists, and clinical teams.
Highlighting the significance of the innovation Dr. Ramesh Hariharan, CEO and Co-Founder of Strand Life Sciences, said, "Early detection is key to fighting and overcoming cancer. CancerSpot represents a major milestone in Strand’s 24-year history of genomics innovation, marking another first for India after years of rigorous research. This facility will not only advance the CancerSpot program but also accelerate the development of novel diagnostics for both Indian and global populations.”
The Centre was inaugurated by Dr. Charles Cantor, a globally renowned genomics expert, in the presence of esteemed guests from the field of genomics.
_20241204111757_original_image_1.webp)
_20241203174723_original_image_1.webp)
